Today, the total Asia-Pacific pharmaceutical markets represent approximately USD 160 billion* and 15.2%* of worldwide
pharmaceutical sales. Menarini Asia-Pacific operates in some of the fastest growing healthcare markets in the world.
The company has achieved a compounded annual growth rate of 20% over the past four years, approximately 4.5 times
the global pharmaceutical market growth.
Menarini Asia-Pacific has instituted proprietary marketing and sales processes to launch and optimise brands across
the region. The rigorous, data-driven approach to marketing leverages proven analytical tools that help arrive at
strategic choices. The unique sales model is tightly integrated with marketing and is customised for the
Menarini Asia-Pacific also utilises a proprietary Launch Playbook to ensure full cross-functional readiness well in
advance of a product launch in areas such as regulatory status optimisation, physician advocacy development, PR,
medical publication planning, consumer activation, trade marketing, and supply chain / channel strategy.
Medical and Regulatory
Menarini Asia-Pacific Regulatory Affairs team's expertise includes registering new products and maintaining of
licenses in 21 markets in the region. The team, comprising of over 50 regulatory professionals, manages licenses
across multiple categories including pharmaceuticals, devices, in vitro diagnostics, cosmetics and food supplements.
Menarini Asia-Pacific Medical Affairs team oversees pharmacovigilance monitoring and reporting across the region. It
also facilitates the access to new products for clinical trials in countries where they are required for
registration, as well as in ensuring fitness of clinical trial data for scientific publication.
Menarini Asia-Pacific operates effectively across a broad range of therapeutic areas: